Marisa Wexler, MS,  senior science writer—

BioCryst is working to develop a new oral therapy for cold agglutinin disease (CAD) that suppresses the immune complement cascade, and expects to have a lead candidate selected by 2025. This and other drug development plans were shared recently by the biotech company in a “R&D Day”…

A bipartisan team of congressional representatives is proposing new legislation that aims to make it easier for people with rare disorders like cold agglutinin disease (CAD) to access treatments that may be beneficial even if they haven’t been formally approved for that indication. The legislation — called the…

In people with cold agglutinin disease (CAD), pre-treatment with rituximab and plasma exchange may help limit complications during surgeries where the patient’s body temperature is decreased, a new report illustrates. The case study, “Total arch replacement for an aortic arch aneurysm with cold agglutinin disease after…

In rare cases, cold agglutinin disease (CAD) may develop as a delayed complication of a combination of immune-activating cancer therapies called immune checkpoint inhibitors (ICIs), according to a case report. While some cases of autoimmune hemolytic anemia (AIHA) — a group of autoimmune disorders that include CAD secondary to…

Daratumumab, which is approved to treat some cancers, was effective at controlling cold agglutinin disease (CAD) in an elderly woman who failed to respond to rituximab, a study reports. The report, “Refractory cold agglutinin disease successfully treated with daratumumab. A case report and review of literature,”…

A man had stroke-like symptoms, a heart attack, and rotting skin that were determined to be likely caused by cold agglutinin disease (CAD). While similar issues have been reported with CAD, this may be the first report of these symptoms occurring at the same time in one patient, the…

A case of cold agglutinin disease (CAD), found to be secondary to a type of blood cancer called B-cell lymphoma, successfully resolved after the cancer was appropriately treated, a study shows. The case report illustrates the importance of identifying the underlying cause of CAD so treatment can be given,…

Specially designed miniaturized antibodies, or nanobodies, reduced blood cell destruction in a new mouse model of a disease similar to cold agglutinin disease (CAD), a study showed. These findings suggest that the nanobodies, designed to suppress the complement cascade by blocking the complement component 2 (C2) protein, could…

Long-term treatment with Enjaymo (sutimlimab-jome) in people with cold agglutinin disease (CAD) results in rapid and sustained reductions in red blood cell destruction and anemia, as well as clinically-meaningful reductions in fatigue. That’s according to 2.5 years of data from the Phase 3 CARDINAL clinical trial, which tested…

An experimental treatment called HMBD-011, designed to target self-reactive antibodies and the immune B-cells that produce them, showed efficacy in a cellular model of cold agglutinin disease (CAD), according to new preclinical findings presented at a scientific conference. “HMBD-011 is a potentially first-in-class … antibody developed for treatment for…